Back to discover

Protein / target

ALK tyrosine kinase receptor

Encoded byALKQ9UM73Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
7
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Receptor signaling protein tyrosine kinase activator

Strongest disease association

Neuroblastoma

Via encoding gene ALK · Genetic evidence · score 0.97

Therapeutic position

Established drug target

Small molecules

Research activity

Emerging research

7 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system.

View complete UniProt function annotation

Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system (PubMed:11121404, PubMed:11387242, PubMed:16317043, PubMed:17274988, PubMed:30061385, PubMed:34646012, PubMed:34819673). Also acts as a key thinness protein involved in the resistance to weight gain: in hypothalamic neurons, controls energy expenditure acting as a negative regulator of white adipose tissue lipolysis and sympathetic tone to fine-tune energy homeostasis (By similarity). Following activation by ALKAL2 ligand at the cell surface, transduces an extracellular signal into an intracellular response (PubMed:30061385, PubMed:33411331, PubMed:34646012, PubMed:34819673). In contrast, ALKAL1 is not a potent physiological ligand for ALK (PubMed:34646012). Ligand-binding to the extracellular domain induces tyrosine kinase activation, leading to activation of the mitogen-activated protein kinase (MAPK) pathway (PubMed:34819673). Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif (PubMed:15226403, PubMed:16878150). Induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1 (PubMed:15226403, PubMed:16878150). ALK activation may also be regulated by pleiotrophin (PTN) and midkine (MDK) (PubMed:11278720, PubMed:11809760, PubMed:12107166, PubMed:12122009). PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation (PubMed:11278720, PubMed:11809760, PubMed:12107166). MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction (PubMed:12122009). Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase (PubMed:15226403, PubMed:16878150). Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK (PubMed:15226403, PubMed:16878150). May function as regulator of gastric epithelial differentiation (By similarity)

Subcellular location

Cell membrane
Domains and Gene Ontology detail (26)

Domains & features

MAM 1LDL-receptor class AMAM 2Protein kinase

Gene Ontology

  • Cextracellular exosome
  • Cplasma membrane
  • Cprotein-containing complex
  • Creceptor complex
  • FATP binding
  • Fheparin binding
  • Fidentical protein binding
  • Fprotein tyrosine kinase activity
  • Freceptor signaling protein tyrosine kinase activator activity
  • Ftransmembrane receptor protein tyrosine kinase activity
  • Pcell surface receptor protein tyrosine kinase signaling pathway
  • Penergy homeostasis

1620 aa · 176 kDa

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Receptor tyrosine kinase signallingUniProt · GOCell proliferation & survivalUniProt · GO
View supporting evidence

Receptor tyrosine kinase signalling

  • ·Neuronal receptor tyrosine kinase that is essentially and transiently expressed in speci…
  • ·transmembrane receptor protein tyrosine kinase activity
  • ·cell surface receptor protein tyrosine kinase signaling pathway

Cell proliferation & survival

  • ·Neuronal receptor tyrosine kinase that is essentially and transiently expressed in speci…
  • ·regulation of cell population proliferation
View underlying pathways (11)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

EML4PTNMDKNPM1KRASNRASPIK3CAPLCG1PIK3R1ALKAL2ALK

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Approved medicines with mapped indications

5 medicines · 3 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Carcinoma, Non-Small-Cell Lung5 medicines
Lymphoma1 medicine
Broader indication categories (1)

Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.

7 medicines meet Open Targets' target-level approved-medicine definition; the 5 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

5

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

lorlatinib
Narrow target profileApprovedInhibitor

ALK tyrosine kinase receptor inhibitor

Indicated for Carcinoma, Non-Small-Cell Lung, Lymphoma, Neoplasms

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

brigatinib
Narrow target profileApprovedInhibitor

ALK tyrosine kinase receptor inhibitor

Indicated for Carcinoma, Non-Small-Cell Lung, Neoplasms

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

ceritinib
Narrow target profileApprovedInhibitor

ALK tyrosine kinase receptor inhibitor

Indicated for Carcinoma, Non-Small-Cell Lung, Neoplasms

Direct interaction with this protein · 1 of 3 recorded protein targets — narrow recorded profile

crizotinib
ApprovedInhibitor

ALK tyrosine kinase receptor inhibitor

Indicated for Carcinoma, Non-Small-Cell Lung, Neoplasms

Direct interaction with this protein · 1 of 6 recorded protein targets

entrectinib
ApprovedInhibitor

ALK tyrosine kinase receptor inhibitor

Indicated for Carcinoma, Non-Small-Cell Lung, Neoplasms

Direct interaction with this protein · 1 of 5 recorded protein targets

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene ALK

Gene-level evidence surfaced through the gene ALKthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Neuroblastoma
0.99Well supported

Genetic evidence dominant · Open Targets 0.84

Neoplasms
0.95Well supported

Clinical evidence dominant · Open Targets 0.73

Neuroblastoma, susceptibility to, 3
0.94Well supported

Genetic evidence dominant · Open Targets 0.76

Carcinoma, Non-Small-Cell Lung
0.92Well supported

Clinical evidence dominant · Open Targets 0.76

Adenocarcinoma of Lung
0.78Well supported

Pathway evidence dominant · Open Targets 0.49

View evidence synthesis (5)
NeuroblastomaWell supported
0.99
agreement 0.911.00
Genetic46%Somatic mutation24%Clinical17%Literature7%Pathway6%Genetic literaturedup

Open Targets aggregate 0.84 · 5 independent evidence families · 1 not counted as duplicate

NeoplasmsWell supported
0.95
agreement 0.861.00
Clinical34%Genetic26%Pathway19%Somatic mutation14%Literature7%

Open Targets aggregate 0.73 · 5 independent evidence families

Neuroblastoma, susceptibility to, 3Well supported
0.94
agreement 0.831.00
Genetic60%Somatic mutation40%Genetic literaturedup

Open Targets aggregate 0.76 · 2 independent evidence families · 1 not counted as duplicate

Carcinoma, Non-Small-Cell LungWell supported
0.92
agreement 0.811.00
Clinical45%Somatic mutation24%Pathway22%Literature9%

Open Targets aggregate 0.76 · 4 independent evidence families

Adenocarcinoma of LungWell supported
0.78
agreement 0.670.89
Pathway32%Clinical30%Somatic mutation28%Literature11%

Open Targets aggregate 0.49 · 4 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Neuroblastoma0.84
Neuroblastoma, susceptibility to, 30.76
Carcinoma, Non-Small-Cell Lung0.76
Neoplasms0.73
Lung Neoplasms0.54
Anaplastic large cell lymphoma0.51
Adenocarcinoma of Lung0.49
Squamous cell lung carcinoma0.47
Lymphoma0.47

Drug development

12 compounds recorded · 7 approved · 5 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 5 drugs that target this protein in Forefront's canonical graph (5 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (10)
LORLATINIBApproval
PLB1003Phase 1
ALECTINIB HYDROCHLORIDEApproval
BRIGATINIBApproval
CRIZOTINIBApproval
ENSARTINIBPhase 3
ASP-3026Phase 1
CONTELTINIBPhase 1 2
ENTRECTINIBApproval
CEP-37440Phase 1

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Approved Drug and Structure with Ligand support this modality.

AntibodiesEmerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (literature and database ubiquitination) — no clinical-stage drug of this modality recorded.

Other modalitiesSupported

Phase 1 Clinical support this modality.

View underlying tractability evidence (13)
SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandSM · High-Quality PocketSM · Druggable FamilyAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMAB · Human Protein Atlas locPR · LiteraturePR · Database UbiquitinationPR · Small Molecule BinderOC · Phase 1 Clinical

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

ClinicalTrials.gov via the drug-target graph.

What's happening now

10

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 5 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. New publication2024-05-31
    Lorlatinib Versus Crizotinib in Patients With Advanced <i>ALK</i>-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · 254 citations · Europe PMC · via lorlatinib

  2. New publication2021-09-16
    Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021 · 300 citations · Europe PMC · via brigatinib

  3. Regulatory approval2020-07-31

    Approval: Rozlytrek (EMA)

    ema · regulatory · ema · via entrectinib

  4. Regulatory approval2019-05-06

    Approval: Lorviqua (EMA)

    ema · regulatory · ema · via lorlatinib

  5. Regulatory approval2018-11-22

    Approval: Alunbrig (EMA)

    ema · regulatory · ema · via brigatinib

  6. Safety communication2015-11-12

    Drug Safety Update: Crizotinib (Xalkori▼): risk of cardiac failure

    mhra · safety · mhra · via crizotinib

  7. Regulatory approval2015-05-06

    Approval: Zykadia (EMA)

    ema · regulatory · ema · via ceritinib

  8. New publication2014-12-01
    First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

    The New England journal of medicine · 2014 · 2,470 citations · Europe PMC · via crizotinib

  9. Regulatory approval2012-10-23

    Approval: Xalkori (EMA)

    ema · regulatory · ema · via crizotinib

  10. New publication2012-01-03
    ROS1 rearrangements define a unique molecular class of lung cancers.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012 · 1,121 citations · Europe PMC · via crizotinib

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.

Research activity

7 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Socinski MA · The New England journal of medicine · 2018

Solomon BJ · The New England journal of medicine · 2014

Shaw AT · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2009

Bergethon K · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012

Camidge DR · Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021

Recent

Lorlatinib Versus Crizotinib in Patients With Advanced <i>ALK</i>-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.

Solomon BJ · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024

Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.

Camidge DR · Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021

Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas.

Guerreiro Stucklin AS · Nature communications · 2019

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Socinski MA · The New England journal of medicine · 2018

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Solomon BJ · The New England journal of medicine · 2014

ROS1 rearrangements define a unique molecular class of lung cancers.

Bergethon K · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

Shaw AT · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2009

Europe PMC papers linked directly to this protein.